RE:With a 15% allowance for "attrition"-look for phase III HALT
Why wouldn't you deduce from your 20 years of experience with Spectral (and with the FDA) that things never go as fast as you would like?
Plus, I don't think that they would have reset the sample size to 176 patients (very small number) only to skip a few cases at the end and therefore weaken the trial's conclusion.
My bet, agains all my hopes, is that the trial will drag on at least down to the target date, and that at that time, we will still be waiting in vain for bold company statements and nice price increases...
because that is the DNA of Spectral. Successful (we will see), but slow and quiet.